Company Filing History:
Years Active: 1993-1998
Title: Mathew Longiaru: Innovator in Synthetic Gene Technology
Introduction
Mathew Longiaru is a notable inventor based in West Orange, NJ (US). He has made significant contributions to the field of synthetic gene technology, holding a total of 3 patents. His work focuses on the construction and expression of synthetic genes, particularly in relation to human retroviruses.
Latest Patents
Longiaru's latest patents include innovative methods for constructing synthetic genes that encode for specific epitopes from the immunodominant conserved region of HTLV-I env. His patents detail a synthetic gene that codes for at least one epitope from HTLV-I env. gp 21, as well as hybrid genes that utilize this synthetic gene in conjunction with other epitopes from HTLV-I env. gp 46 and gp 21. The patents also cover the corresponding gene products, recombinant vectors containing the genes, methods for producing the polypeptides, and methods for detecting antibodies to HTLV-I using these polypeptides.
Career Highlights
Throughout his career, Mathew Longiaru has worked with prominent companies in the biotechnology sector, including Hoffmann-La Roche Inc. and Roche Diagnostic Systems, Inc. His experience in these organizations has allowed him to develop and refine his expertise in synthetic gene technology.
Collaborations
Longiaru has collaborated with several notable professionals in his field, including Deborah Anne Buonagurio and Sheryl B. Silver. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Mathew Longiaru's innovative work in synthetic gene technology has positioned him as a key figure in the field. His patents and collaborations reflect his commitment to advancing scientific knowledge and improving methods for detecting and understanding human retroviruses.